2507-80-4

Upstream product

• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 393107-91-0 ethyl 6-(4-methoxyphenyl)imidazo [2,1-b]thiazole-3-carboxylate 
• 6039-97-0 3H-thiazol-2-one 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 96-50-4 2-thiazolylamine 
• 875289-81-9 2,4-dinitro-benzenesulfonic acid 2-(4-methoxy-phenyl)-2-oxo-ethyl ester 
• 93435-57-5 α-tosyloxy-p-methoxyacetophenone 
• 92754-21-7 2-amino-3-[2-(4-methoxy-phenyl)-2-oxo-ethyl]-thiazolium; bromide 

Downstream Products

• 134670-24-9 5-deuterio-6-p-methoxyphenylimidazo<2,1-b>thiazole 
• 134670-25-0 6-p-Methoxyphenyl-5-nitrosoimidazo<2,1-b>thiazole 
• 134670-26-1 6-(4-methoxyphenyl)imidazo[2,1-b]thiazole-5-carbaldehyde 
• 1257653-80-7 (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1Hpyrrol-2-yl)prop-2-en-1-one 
• 1257653-81-8 (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(thien-2-yl)prop-2-en-1-one 
• 1257653-82-9 (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,5-difluorophenyl)prop-2-en-1-one 
• 1257653-83-0 (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(Benzo[d][1,3]dioxol-5-yl)prop-2-en-1-one 
• 1257653-85-2 (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one 
• 1257653-71-6 (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1408000-87-2 3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)quinoxalin-2(1H)-one 
• 1408000-88-3 3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-6,7-dimethylquinoxalin-2(1H)-one 
• 1408000-89-4 3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)benzo[g]quinoxalin-2(1H)-one 
• 1408000-78-1 ethyl 2-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-2-oxoacetate 
• 815596-28-2 6-(4-methoxyphenyl)-5-(2-(methylthio)pyrimidin-4-yl)imidazo[2,1-b]thiazole 

Relevant academic research and scientific papers

Hypervalent iodine in the synthesis of bridgehead heterocycles: A facile route to the synthesis of 6-arylimidazo[2,1-b]thiazoles using [hydroxy(tosyloxy)iodo]benzene

α-Tosyloxyketones (2), readily accessible through hypervalent iodine oxidation of enolizable ketones (1) using [hydroxy(tosyloxy)iodo]benzene (HTIB) in acetonitrile, exclusively generates the 6-arylimidazo[2,1-b]thiazoles (4) on treatment with commerciall

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors

This article reports on novel imidazothiazole derivatives as first-in-class potent and selective ErbB4 (HER4) inhibitors. There are no other reported selective inhibitors of this kinase in the literature, that's why they are considered as first-in-class. In addition, none of the reported non-selective ErbB4 inhibitors possesses imidazothiazole nucleus in its structure. Therefore, there is novelty in this work in both kinase selectivity and chemical structure. Compounds Ik and IIa are the most potent ErbB4 kinase inhibitor (IC50 = 15.24 and 17.70 nM, respectively). Compound Ik showed promising antiproliferative activity. It is selective towards cancer cell lines than normal cells. Its ability to penetrate T-47D cell membrane and inhibit ErbB4 kinase inside the cells has been confirmed. Moreover, both compound Ik and IIa have additional merits such as weak potency against hERG ion channels and against CYP 3A4 and 2D6. Molecular docking and dynamic simulation studies were carried out to explain binding interactions.

New imidazo[2,1-: B] thiazole-based aryl hydrazones: Unravelling their synthesis and antiproliferative and apoptosis-inducing potential

Herein, we have designed and synthesized new imidazo[2,1-b]thiazole-based aryl hydrazones (9a-w) and evaluated their anti-proliferative potential against a panel of human cancer cell lines. Among the synthesized compounds, 9i and 9m elicited promising cytotoxicity against the breast cancer cell line MDA-MB-231 with IC50 values of 1.65 and 1.12 μM, respectively. Cell cycle analysis revealed that 9i and 9m significantly arrest MDA-MB-231 cells in the G0/G1 phase. In addition, detailed biological studies such as annexin V-FITC/propidium iodide, DCFH-DA, JC-1 and DAPI staining assays revealed that 9i and 9m triggered apoptosis in MDA-MB-213 cells. Overall, the current work demonstrated the cytotoxicity and apoptosis-inducing potential of 9i and 9m in breast cancer cells and suggested that they could be explored as promising antiproliferative leads in the future. This journal is

DL5050, a Selective Agonist for the Human Constitutive Androstane Receptor

The constitutive androstane receptor (CAR) is a xenobiotic sensor governing the transcription of genes involved in drug disposition, energy homeostasis, and cell proliferation. However, currently available human CAR (hCAR) agonists are nonselective, which

Human constitutive androstane receptor agonist DL5016: A novel sensitizer for cyclophosphamide-based chemotherapies

The DNA alkylating prodrug cyclophosphamide (CPA), alone or in combination with other agents, is one of the most commonly used anti-cancer agents. As a prodrug, CPA is activated by cytochrome P450 2B6 (CYP2B6), which is transcriptionally regulated by the

Synthesis of new triazole fused imidazo[2,1-b]thiazole hybrids with emphasis on Staphylococcus aureus virulence factors

A series of new triazole fused imidazo[2,1-b]thiazole hybrids (9a–u) were designed, synthesized and evaluated as antimicrobial agents. Compounds 9c, 9d, 9e, 9j and 9l showed promising broad spectrum antimicrobial activity. Further, compound 9c exhibited s

Metal-Free Aerobic Oxidative Selective C-C Bond Cleavage in Heteroaryl-Containing Primary and Secondary Alcohols

A transition-metal-free aerobic oxidative selective C-C bond-cleavage reaction in primary and secondary heteroaryl alcohols is reported. This reaction was highly efficient and tolerated various heteroaryl alcohols, generating a carboxylic acid derivative and a neutral heteroaromatic compound. Experimental studies combined with density functional theory calculations revealed the mechanism underlying the selective C-C bond cleavage. This strategy also provides an alternative simple approach to carboxylation reaction.

A copper-catalyzed multi-component reaction accessing fused imidazo-heterocycles via C-H functionalization

An efficient synthesis of fused imidazo-heterocycles is described using Cu(OTf)2 in [bmim]BF4 by the multi-component reaction of pyridin-2(1H)-one or thiazol/benzo[d]thiazol-2(3H)-ones with O-tosylhydroxyl amine and acetophenones under microwave irradiation. The present method is very rapid and the product formation occurs via a C-H functionalization/tandem addition-cyclization process. The ionic liquid containing copper triflate is recovered and reused four times.

Microwave assisted synthesis of novel imidazo [2,1-b]thiazole derivative attached to quinoxalinones

3-(6-Phenylimidazo[2,1-b]thiazol-5-yl)quinoxalin-2(1H)-ones (qunoxalinone) (6a-q) have been synthesized by the reaction of ethyl 2-oxo-2-(6- phenylimidazo[2,1-b]thiazol-5-yl)acetates (4a-e) with suitably substituted o-phenylenediamines (5a-f) under microw